Logo

American Heart Association

  25
  0


Final ID: TU219

Impact of Adverse Pregnancy Outcomes on Long-term Outcomes in Women with Heart Failure

Abstract Body: Introduction: Adverse pregnancy outcomes (APOs) are risk factors for future cardiovascular disease, including heart failure (HF). However, the impact of a history of APOs among women diagnosed with HF is unclear. We investigated whether women with HF and a history of APOs, including gestational hypertension, preeclampsia, eclampsia, gestational diabetes mellitus, and fetal growth restriction, experienced worse long-term HF-related outcomes than those without APOs.

Methods: Using the TriNetX Global Collaborative Network, we conducted a retrospective cohort study of women aged 25-80 years with HF (both HFpEF and HFrEF) and a history of pregnancy. Cohort 1 included women with prior APOs (ICD O13-15, O16.1, O254.41, O36.59), and Cohort 2 included women with documented pregnancy but no APOs, all based on International Classification of Diseases, 10th Revision (ICD-10) encounter diagnosis. Cohorts were propensity-score matched (PSM) on 27 variables, including demographics and established cardiovascular comorbidities, yielding 5,061 matched pairs. Index event was the date of initial documented HF diagnosis (I50). Baseline characteristics were evaluated over 5 years preceeding the index date. Outcomes were assessed over 10 years following index and included HF exacerbations (I50.23, I50.33, I50.31, I50.21, I50.43, I50.51), ischemic stroke (I63), myocardial infarction (I21), and all-cause mortality. Statistical analyses were performed using Z-statistics and Kaplan-Meier survival analyses.

Results: Cohorts were well matched demographically (mean age 45.7 vs 45.4 years; 47.9% vs 46.9% White; 36.7% vs 37.3% Black) and across all major cardiovascular risk factors after PSM. Women with APOs had significantly higher rates of HF exacerbations (44.6% vs 39.2%, HR 1.19, 95% CI 1.12–1.26, p<0.001). No significant differences were observed in ischemic stroke (p=0.284), myocardial infarction (p=0.166), or all-cause mortality (p=0.931).

Conclusions: Among women with HF, a history of APOs is associated with more HF exacerbations. These findings highlight APO history as an important marker for identifying women who may benefit from more intensive HF management.
  • Thaker, Vishrut  ( Emory University School of Medicine , Morrow , Georgia , United States )
  • Mouawad, Celine  ( Emory University School of Medicine , Morrow , Georgia , United States )
  • Evenhuis, Bernard  ( Emory University School of Medicine , Morrow , Georgia , United States )
  • Ahmed, Taha  ( Emory University School of Medicine , Morrow , Georgia , United States )
  • Kaelber, David  ( Case Western Reserve University , Shaker Heights , Ohio , United States )
  • Chandrasekaran, Suchitra  ( Emory University School of Medicine , Morrow , Georgia , United States )
  • Mehta, Puja  ( Emory University School of Medicine , Morrow , Georgia , United States )
  • Author Disclosures:
Meeting Info:

EPI-Lifestyle Scientific Sessions 2026

2026

Boston, Massachusetts

Session Info:

Poster Session 1

Tuesday, 03/17/2026 , 05:00PM - 07:00PM

Poster Session

More abstracts on this topic:
Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Insights from the All of Us Research Program

Renedo Daniela, Schwamm Lee, Kamel Hooman, Matouk Charles, Tal Reshef, Sheth Kevin, Falcone Guido, Chaves-rivera Maria Natalia, Rivier Cyprien, Koo Andrew, Clocchiatti-tuozzo Santiago, Huo Shufan, Sujijantarat Nanthiya, Torres Lopez Victor, Hebert Ryan

ANSWER-HF: A Randomized Controlled Trial of Sacubitril/Valsartan Versus Enalapril in Patients with Chronic Chagas Cardiomyopathy and Reduced Ejection Fraction

Madrini Junior Vagner, Antunes Talita, Damiani Lucas, Jose Grupi Cesar, Mathias Junior Wilson, Lopes Renato, Ramires Felix, Ramos Souza Paulo, Fernandes Fabio, Maria Ianni Barbara, Silva Martins Alan, JadÁn Luzuriaga Georgina Del Cisne, Cardoso Barbosa Fonseca Keila, Ribeiro Orlando, Bispo Da Cruz Allecineia

More abstracts from these authors:
SGLT2 Inhibitors Are Associated with Improved Outcomes in HFpEF Patients with ESRD

Evenhuis Bernard, Weiss Allison, Rim Austin, Ahmed Taha, Kaelber David, Mehta Puja

Cardiorenal Benefits of SGLT2 Inhibitors in HFrEF Patients with ESRD Requiring Dialysis

Weiss Allison, Evenhuis Bernard, Ahmed Taha, Mehta Puja

You have to be authorized to contact abstract author. Please, Login
Not Available